Lawton Alison Frances has filed 5 insider transactions across 3 companies since June 2023.
Most recent transaction: a grant/award of 12500 shares of Dianthus Therapeutics, Inc. /DE/ ($DNTH) on May 22, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 22, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Lawton Alison Frances | Not found | A | Stock Option (Right to Buy) | 12500 | $0.00 | 12,500.0000 | 32,125,179 | 9999.99% | 0.04% |
| June 10, 2024 | X4 Pharmaceuticals, Inc | $XFOR | Lawton Alison Frances | Director | A | Common Stock | 45000 | $0.00 | 96,667.0000 | 177,812,480 | 87.10% | 0.03% |
| May 23, 2024 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Lawton Alison Frances | Not found | A | Stock Option (Right to Buy) | 11000 | $0.00 | 11,000.0000 | 0 | 9999.99% | 0.00% |
| June 22, 2023 | Spyre Therapeutics, Inc. | $SYRE | Lawton Alison Frances | Director | A | Stock Option (right to buy) | 1950000 | $0.00 | 1,950,000.0000 | 0 | 9999.99% | 0.00% |
| June 13, 2023 | X4 Pharmaceuticals, Inc | $XFOR | Lawton Alison Frances | Director | A | Common Stock | 45000 | $0.00 | 51,667.0000 | 63,525,845 | 674.97% | 0.07% |